Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06313567
PHASE3

Metronomic Capecitabine in Stage III Gastric Cancer

Sponsor: Fudan University

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.

Official title: Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

722

Start Date

2024-03-10

Completion Date

2029-03-10

Last Updated

2024-07-08

Healthy Volunteers

No

Conditions

Interventions

DRUG

Metronomic capecitabine group

500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group

OTHER

Observation

observation

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China